Related Experiment Video
Updated: May 7, 2025
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
[Detection and interpretation of PD-L1 in urologic neoplasms]
1Department of Pathology, The University of Hong Kong-Shenzhen Hospital, Shenzhen518053, China.
Abstract:
Immune checkpoint inhibitors targeting PD-1/PD-L1 are gradually being applied in the treatment of advanced urinary system tumors. Immunohistochemical analysis of PD-L1 expression is the most popular method for screening suitable patients for immunotherapy and predicting therapeutic efficacy. The current application status of PD-L1 detection for urinary system tumors (mainly urothelial carcinoma), methods of the different antibody tests and the precautions, challenges and solutions in the interpretation of immunostaining were summarized in this review.
Insights
Immune checkpoint inhibitors targeting PD-1/PD-L1 show promise for advanced urinary tumors. This review details PD-L1 testing methods, challenges, and interpretation for predicting immunotherapy success in urothelial carcinoma.
Area of Science:
- Oncology
- Immunology
- Pathology
Background:
- Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 are increasingly used for advanced urinary system tumors.
- PD-L1 expression analysis via immunohistochemistry is crucial for patient selection and efficacy prediction in ICI therapy.
Purpose of the Study:
- To review the current status of PD-L1 detection in urinary system tumors, primarily urothelial carcinoma.
- To discuss various antibody tests, interpretation challenges, and solutions for PD-L1 immunostaining.
Main Methods:
- Literature review of PD-L1 detection methods in urothelial carcinoma.
- Analysis of different antibody clones and detection platforms for PD-L1 expression.
- Summary of guidelines and expert opinions on PD-L1 interpretation.
Main Results:
- PD-L1 testing is a key biomarker for guiding immunotherapy in advanced urothelial carcinoma.
- Various antibody assays exist, each with specific protocols and potential for variability.
- Interpretation of PD-L1 staining presents challenges including scoring systems and tumor heterogeneity.
Conclusions:
- Standardized PD-L1 testing and interpretation are essential for optimizing immunotherapy in urinary system tumors.
- Addressing challenges in PD-L1 detection will improve patient stratification and treatment outcomes.
- Further research is needed to refine PD-L1 assays and predictive models for urothelial carcinoma.
